Alzamend Neuro Regains Nasdaq Compliance After Exceeding Equity Requirement

Key Points

• Alzamend Neuro has regained compliance with Nasdaq’s continued-listing requirements.
• The company reported stockholders’ equity of approximately $5.8 million as of July 31, 2026, above Nasdaq’s $2.5 million minimum requirement.
• Nasdaq confirmed that Alzamend now complies with Listing Rule 5550(b)(1) and closed the matter.
• The company had previously received a Nasdaq deficiency notice in March 2026 and was given until September 16, 2026, to regain compliance.
• Alzamend said it will now focus on advancing AL001 through four Phase II clinical trials with Massachusetts General Hospital.

Alzamend Neuro (NASDAQ: ALZN) has regained compliance with Nasdaq listing standards after demonstrating stockholders’ equity above the exchange’s required minimum.

Nasdaq notified the company on September 14 that it now complies with the stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1), closing the compliance matter. 

Alzamend Reports $5.8 Million in Stockholders’ Equity

To regain compliance, Alzamend needed to report at least $2.5 million in stockholders’ equity.

According to its Form 10-Q for the quarter ended July 31, 2026, Alzamend reported stockholders’ equity of $5,802,680. That amount exceeded Nasdaq’s minimum threshold by approximately $3.3 million.

Nasdaq Closes Earlier Listing Deficiency Matter

Alzamend was first notified by Nasdaq on March 20, 2026, that it did not meet the minimum market value of listed securities requirement or another applicable continued-listing standard, including the equity requirement.

The company was initially given until May 4, 2026, to submit a plan to restore compliance. Nasdaq accepted Alzamend’s plan and gave the company until September 16, 2026, to meet the equity standard.

With Nasdaq confirming compliance on September 14, Alzamend resolved the issue ahead of that deadline.

Company Focuses on AL001 Phase II Clinical Trials

Alzamend said it will now focus on advancing AL001 through four Phase II clinical trials in partnership with Massachusetts General Hospital.

The company said the healthy-volunteer portion of the program began in May 2025, completed its clinical phase in November 2025, and produced topline data in March 2026.

Alzamend began a bipolar-disorder cohort in April 2026. The company plans to complete that trial and then sequentially begin additional cohorts involving patients with Alzheimer’s disease, major depressive disorder, and post-traumatic stress disorder.